- Home
- TORO vs IOBT Comparison
TORO vs IOBT Comparison
Compare TORO & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- IOBT
- Stock Information
- Founded
- TORO 2022
- IOBT 2014
- Country
- TORO Cyprus
- IOBT Denmark
- Employees
- TORO N/A
- IOBT N/A
- Industry
- TORO Marine Transportation
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- IOBT Health Care
- Exchange
- TORO Nasdaq
- IOBT Nasdaq
- Market Cap
- TORO 55.1M
- IOBT 59.3M
- IPO Year
- TORO N/A
- IOBT 2021
- Fundamental
- Price
- TORO $2.54
- IOBT $0.90
- Analyst Decision
- TORO
- IOBT Strong Buy
- Analyst Count
- TORO 0
- IOBT 3
- Target Price
- TORO N/A
- IOBT $9.33
- AVG Volume (30 Days)
- TORO 22.9K
- IOBT 133.1K
- Earning Date
- TORO 03-18-2025
- IOBT 03-18-2025
- Dividend Yield
- TORO N/A
- IOBT N/A
- EPS Growth
- TORO N/A
- IOBT N/A
- EPS
- TORO 0.99
- IOBT N/A
- Revenue
- TORO $80,626,531.00
- IOBT N/A
- Revenue This Year
- TORO N/A
- IOBT N/A
- Revenue Next Year
- TORO N/A
- IOBT N/A
- P/E Ratio
- TORO $0.90
- IOBT N/A
- Revenue Growth
- TORO 52.03
- IOBT N/A
- 52 Week Low
- TORO $2.25
- IOBT $0.66
- 52 Week High
- TORO $6.06
- IOBT $1.85
- Technical
- Relative Strength Index (RSI)
- TORO 36.37
- IOBT 44.94
- Support Level
- TORO $2.46
- IOBT $0.82
- Resistance Level
- TORO $2.62
- IOBT $0.96
- Average True Range (ATR)
- TORO 0.10
- IOBT 0.10
- MACD
- TORO -0.01
- IOBT -0.02
- Stochastic Oscillator
- TORO 27.59
- IOBT 21.05
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.